2022
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activities
2021
Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa
Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2100685118. PMID: 34261791, PMCID: PMC8307356, DOI: 10.1073/pnas.2100685118.Peer-Reviewed Original ResearchConceptsWild-type genotypeFirst-line ACTPartner drug resistanceSaharan AfricaCombination therapyPartner drugs
2020
Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study
Ehrlich HY, Jones J, Parikh S. Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study. The Lancet Microbe 2020, 1: e209-e217. PMID: 33089222, PMCID: PMC7575134, DOI: 10.1016/s2666-5247(20)30094-x.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyPartner drug resistanceDrug resistanceSurveillance dataDrug resistance surveillanceACT partner drugsMalaria-endemic countriesSentinel surveillance systemDrug surveillance dataAntimalarial drug resistanceSaharan AfricaPartner drugsCombination therapyAntimalarial resistanceSurveillance sitesMarker prevalenceResistance surveillanceMedian time lagMolecular surveillanceSystematic searchResistance-associated markersMean amountSub-Saharan countries
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply